PATH Share Price

Open 4.20 Change Price %
High 4.33 1 Day 0.07 1.67
Low 4.18 1 Week 0.00 0.00
Close 4.25 1 Month 0.00 0.00
Volume 657476 1 Year 0.00 0.00
52 Week High 4.44
52 Week Low 0.00
PATH Important Levels
Resistance 2 4.39
Resistance 1 4.33
Pivot 4.25
Support 1 4.17
Support 2 4.11
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ETRM 0.07 0.00%
AAPL 113.86 1.55%
AAPL 113.86 1.55%
More..
NASDAQ USA Top Gainers Stocks
HTCO 11.00 62.96%
LOCM 0.09 50.00%
OPXA 1.21 40.70%
QKLS 0.18 38.46%
ZAZA 0.08 33.33%
MOSY 0.46 31.43%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
PPHM 0.40 25.00%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
BGMD 0.05 -37.50%
More..

NuPathe Inc. (NASDAQ: PATH)

PATH Technical Analysis 5
As on 21st Feb 2014 PATH Share Price closed @ 4.25 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 2.95 & Strong Buy for SHORT-TERM with Stoploss of 3.64 we also expect STOCK to react on Following IMPORTANT LEVELS.
PATH Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
PATH Other Details
Segment EQ
Market Capital 52411492.00
Sector Consumer Durables Major Pharmaceuticals
Industry
Offical website
PATH Address
PATH
N/A
PATH Latest News
Drug developer NuPathe shares dip in market debut   Ventura County Star   - 08th Jul 16
Fibrocell Appoints Michael F. Marino as Senior Vice President, General Counsel ...   GlobeNewswire (press release)   - 02nd Jun 15
Fibrocell Science Appoints Keith A. Goldan, Senior Vice President and Chief ...   GlobeNewswire (press release)   - 19th Mar 15
AgeneBio Appoints Industry Leaders Patrick LePore as Chairman of the Board and ...   Marketwired (press release)   - 25th Jul 14
Exclusive: Big payday for executives after $144M NuPathe-Teva deal   Philadelphia Business Journal (blog)   - 04th Mar 14
Teva Completes Tender Offer for NuPathe Inc. Shares   Business Wire (press release)   - 21st Feb 14
Teva to Acquire NuPathe for $144 Million, Outbidding Endo   Bloomberg   - 21st Jan 14
Endo Health to acquire Nupathe for $105 million   Reuters   - 16th Dec 13
NuPathe Doses Adolescent Migraineurs in Clinical Study of ZECUITY   Marketwired (press release)   - 23rd Sep 13
NuPathe Wins US FDA Approval for Migraine Skin Patch   Bloomberg   - 18th Jan 13
Interactive Technical Analysis Chart NuPathe Inc. ( PATH NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on NuPathe Inc.
PATH Business Profile
NuPathe, Inc. develops therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. The Companys products are NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The Company completed a pivotal Phase III clinical trial for Zelrix, an active, single-use transdermal sumatriptan patch for the treatment of acute migraine.